ClinicalTrials.gg

Program

ABBV-295

A development code.

In AbbVie's pipeline, Long-Acting Amylin Analog. Its studies are mostly in Obesity · Psoriasis, led by AbbVie.

Furthest: phase 2, since Aug 4, 20265 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie54 open or runningphase 2since Aug 4, 2026Nov 19, 2025Dec 2026phase 1 · NCT07514260
  • Named in AbbVie’s own pipeline as ABBV-295, phase 2, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 19, 2025First study: phase 1 study in ObesityFirst studyNCT07291232 · 80 enrolled · United States
  2. Feb 11, 2026Phase 1 study in Healthy VolunteerNCT07414784 · 20 enrolled · United States
  3. Mar 31, 2026Phase 1 study in Healthy VolunteerNCT07514260 · 24 enrolled · United States
  4. Aug 4, 2026Phase 2 study in ObesityPhase 2 reachedNCT07752979 · 360 planned · United States, Puerto Rico
  5. Nov 6, 2026Phase 2 study in PsoriasisNCT07933536 · 105 planned

Ahead

  1. Dec 2026Primary completion: phase 1 study in Healthy VolunteerNCT07514260
  2. Apr 2027Primary completion: phase 1 study in ObesityNCT07291232
  3. Mar 2028Primary completion: phase 2 study in ObesityNCT07752979
  4. Dec 2028Primary completion: phase 2 study in PsoriasisNCT07933536

TargetBeta

“Long-Acting Amylin Analog”the company's pipeline, read by Claude · source

Other programs on CALCR

ProgramCompanyFurthest phaseStudies
cagrilintideNovo Nordiskphase 350
zenagamtideNovo Nordiskphase 335
petrelintideruleZealand Pharmaphase 311
PF-08653945Pfizerphase 22
GUB014295AbbViephase 11
CagriSema ANovo Nordiskphase 11

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07933536Psoriasis2Not yet recruitingDec 2028105
NCT07752979Obesity · United States, Puerto Rico2RecruitingMar 2028360
NCT07514260Healthy Volunteer · United States1Active, not recruitingDec 202624
NCT07414784Healthy Volunteer · United States1CompletedAug 4, 202620
NCT07291232Obesity · United States1Active, not recruitingApr 202780

How it is read

Names in the registry

  • “ABBV-295”, 5 entries

Codes read as this program: ABBV295.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.